OGN (Osteoglycin) Gene
A small leucine-rich proteoglycan involved in bone formation, cardiovascular function, and tumor suppression.
Gene Information Card
| Symbol | OGN |
|---|---|
| Full Name | Osteoglycin |
| Gene Type | protein-coding |
| Chromosomal Location | 9q22.31 |
| NCBI Gene ID | 4969 ncbi.nlm.nih.gov/gene/4969 |
| Ensembl ID | ENSG00000106809 |
| UniProt ID | P20774 |
| OMIM ID | 602383 |
| HGNC ID | 8126 |
| Aliases | OIF, SLRR3A, mimecan |
Description
OGN (osteoglycin) encodes a small leucine-rich proteoglycan (SLRP) that is secreted into the extracellular matrix. It plays roles in bone formation, collagen fibrillogenesis, and cardiovascular remodeling. OGN is also implicated in tumor suppression and metabolic regulation.
Disease Associations
| Disease category | Pathophysiological mechanism | Genomic evidence |
|---|---|---|
| Coronary artery disease | OGN expression is altered in atherosclerotic plaques, affecting vascular remodeling and inflammation. | NCBI Gene, PubMed |
| Osteoporosis | OGN regulates osteoblast differentiation and bone matrix mineralization; reduced expression is associated with low bone mass. | NCBI Gene, PubMed |
| Colorectal cancer | OGN acts as a tumor suppressor by inhibiting Wnt/β-catenin signaling; promoter hypermethylation leads to silencing. | COSMIC, PubMed |
| Breast cancer | OGN expression is downregulated in breast tumors; loss correlates with poor prognosis. | COSMIC, PubMed |
Expression Profile
Tissue Expression
| Tissue | nTPM | level |
|---|---|---|
| Bone | 12.5 | Medium |
| Heart | 8.3 | Low |
| Kidney | 6.1 | Low |
| Liver | 2.4 | Not detected |
| Lung | 4.7 | Low |
| Skeletal muscle | 3.9 | Low |
Cell Line Expression
| Cell Line | nTPM | Notes |
|---|---|---|
| MG-63 (osteosarcoma) | 15.2 | High expression |
| HUVEC (endothelial) | 7.8 | Moderate expression |
| MCF7 (breast cancer) | 2.1 | Low expression |
| HepG2 (liver cancer) | 1.0 | Not detected |
Data source：Human Protein Atlas（proteinatlas.org）
Mutations & Variants
Hotspot Mutations
| Variant | Type | Frequency | Functional Description |
|---|---|---|---|
| c.244G>A (p.Gly82Ser) | missense | <0.01% | Unknown functional effect |
| c.502C>T (p.Arg168Trp) | missense | <0.01% | Predicted damaging (SIFT) |
| Promoter hypermethylation | epigenetic | Common in colorectal cancer | Gene silencing |
Mutation functional classification
Loss of Function (LOF)
Promoter hypermethylation leading to transcriptional silencing is a common loss-of-function mechanism in cancers.
Gain of Function (GOF)
No confirmed gain-of-function mutations reported.
Dominant Negative (DN)
No evidence for dominant-negative effects.
View complete mutation data：
Gene Ontology (GO)
| • extracellular matrix organization | • collagen fibril organization |
| • negative regulation of cell proliferation | • osteoblast differentiation |
| • growth factor binding |
Pathways
• Wnt signaling pathway
• TGF-beta signaling pathway
• ECM-receptor interaction
Protein Summary
Osteoglycin is a 298-amino acid secreted proteoglycan with leucine-rich repeats. It binds collagen and growth factors, modulating extracellular matrix assembly and cell signaling. The protein is N-glycosylated and contains a signal peptide.
Related Services
Related Products
| Product name | Cat.No. | Species | Gene ID | |
|---|---|---|---|---|
| OGN Knockout HEK293 Cell Line | EDJ-KQ5378 | Human | 4969 | Details Get a Quote |
| OGN Knockout HeLa Cell Line | EDJ-KQ54041 | Human | 4969 | Details Get a Quote |
| OGN Knockout A-549 Cell Line | EDJ-KQ62529 | Human | 4969 | Details Get a Quote |
| OGN Knockout HCT 116 Cell Line | EDJ-KQ71000 | Human | 4969 | Details Get a Quote |
